Boehringer Ingelheim Animal Health expanded its telemedicine offerings today to help veterinarians and pet owners care for animals at a time of social distancing and beyond.
The PetPro Tele+™ platform provides an all-in-one telemedicine solution that people can access online for immediate use. It allows mobile-to-mobile appointments between veterinarians and pet owners who are limiting personal interaction to prevent the spread of the virus that causes COVID-19.
« Now more than ever, we are committed to helping veterinary clinics and pet owners continue to care for animals during an unprecedented public health crisis, » said Randolph Legg, Head of the U.S. Commercial Business for Boehringer Ingelheim Animal Health. « We designed the PetPro Tele+ platform for veterinarians and pet owners who want to get up and running with telemedicine within minutes. »
PetPro Tele+ is a standalone, telemedicine version of PetPro Connect™, a digital ecosystem that Boehringer Ingelheim introduced in select U.S. markets in 2019. In March, as social distancing decreased in-person clinic visits, Boehringer Ingelheim made PetPro Connect available at no cost to veterinarians around the U.S. who need a solution that fully integrates with a practice management system.
PetPro Tele+ and PetPro Connect both let veterinarians and pet owners schedule appointments and communicate by video and chat. They both are free. One key difference is that since PetPro Tele+ does not require integration with a practice management system, people can start using it within minutes. It also lets pet owners share photos, videos and other info with a veterinarian before and/or during a virtual appointment.
PetPro Tele+ is innovating telemedicine by delivering relevant, helpful pet care and clinic-related content from premier industry partners. This includes important and timely COVID-19 information along with engaging tips for pet owners.
PetPro Tele+ is available in the United States at www.petproconnect.com/teleplus and soon will be available for download on your preferred mobile device. Boehringer Ingelheim plans to introduce it soon in several other countries.
Lire la suite: www.ptcommunity.com